It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
We investigated clinical associations of ficolins and mannose-binding lectin (MBL) in 157 patients suffering from acute myeloid leukaemia (AML). Concentrations of ficolin-1, ficolin-2, ficolin-3 and MBL (before chemotherapy) in serum were determined as were selected polymorphisms of the corresponding genes (FCN1, FCN2, FCN3 and MBL2). The control group (C) consisted of 267 healthy unrelated individuals. Median level of ficolin-1 in patients was lower (p < 0.000001) while median levels of ficolin-2, ficolin-3 and MBL were higher (p < 0.000001, p < 0.000001 and p = 0.0016, respectively) compared with controls. These findings were generally associated with AML itself, however the highest MBL levels predicted higher risk of severe hospital infections (accompanied with bacteremia and/or fungaemia) (p = 0.012) while the lowest ficolin-1 concentrations tended to be associated with prolonged (> 7 days) fever (p = 0.026). Genotyping indicated an association of G/G homozygosity (corresponding to FCN1 gene − 542 G > A polymorphism) with malignancy [p = 0.004, OR = 2.95, 95% CI (1.41–6.16)]. Based on ROC analysis, ficolin-1, -2 and -3 may be considered candidate supplementary biomarkers of AML. Their high potential to differentiate between patients from non-malignant controls but also from persons suffering from other haematological cancers (multiple myeloma and lymphoma) was demonstrated.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Polish Academy of Sciences, Laboratory of Immunobiology of Infections, Institute of Medical Biology, Lodz, Poland (GRID:grid.413454.3) (ISNI:0000 0001 1958 0162)
2 Institute of Hematology and Transfusion Medicine, Department of Hematology, Warsaw, Poland (GRID:grid.419032.d) (ISNI:0000 0001 1339 8589)
3 Copernicus Memorial Hospital in Łódź Comprehensive Cancer Center and Traumatology, Department of Hematology, Lodz, Poland (GRID:grid.413767.0)
4 Medical University of Łódź, Department of Hematology, Lodz, Poland (GRID:grid.8267.b) (ISNI:0000 0001 2165 3025)
5 Medical University of Łódź, Department of Immunology and Allergy, Lodz, Poland (GRID:grid.8267.b) (ISNI:0000 0001 2165 3025); Medical University of Łódź, Department of Rheumatology, Lodz, Poland (GRID:grid.8267.b) (ISNI:0000 0001 2165 3025)
6 Medical University of Łódź, Department of Immunology and Allergy, Lodz, Poland (GRID:grid.8267.b) (ISNI:0000 0001 2165 3025)
7 Aarhus University, Department of Biomedicine, Aarhus C, Denmark (GRID:grid.7048.b) (ISNI:0000 0001 1956 2722)
8 Tokai University, Department of Applied Biochemistry, Hiratsuka, Japan (GRID:grid.265061.6) (ISNI:0000 0001 1516 6626)